Navigation Links
Pierre Fabre Dermatologie Starts Clinical Trials on a Beta-Blocker to Treat Severe Infantile Haemangioma
Date:5/6/2009

CASTRES, France, May 6 /PRNewswire/ -- Pierre Fabre Dermatologie, specialised department of Pierre Fabre Laboratories, is proud to announce the launch of a set of clinical trials following the signature of an exclusive and worldwide licence agreement on July 10th 2008 with the University of Bordeaux. The contract covers the development, production and marketing of a paediatric beta-blocker for the treatment of severe infantile haemangioma with the intention of obtaining NDA-approval (New Drug Application) both for Europe and the USA. Patents were also applied for in this indication.

The efficacy of beta-blockers on haemangioma was discovered by Dr. Christine Leaute- Labreze, dermatologist in Pr. Alain Taieb's department in Bordeaux. "Effectiveness of this treatment has been demonstrated in several hundred children throughout the world. Rigorous clinical trials are, however, yet to be conducted to ascertain the efficacy and tolerance of this new therapeutic strategy, hence this agreement with Pierre Fabre Dermatologie, which would ensure safety and availability of the treatment."

This therapeutic breakthrough has been widely talked about, not only during scientific conferences but also through professional and general-interest press.

"This is a major discovery that will bring true therapeutic advance to patients affected by this highly apparent disease, which can be very severe and can have a strong impact on their quality of life and that of their parents. For this reason, we are highly honoured to have signed this agreement with the University of Bordeaux on severe haemangioma," specifies Jacques Fabre, General Manager of Pierre Fabre Dermocosmetique.

About haemangioma:

Infantile haemangioma refers to a vascular tumour highly prevalent in infants, with a 10% concurrency rate. Haemangioma occurs in the first months of life and is located on the face in 60% of cases
'/>"/>

SOURCE Pierre Fabre SA
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Bristol-Myers Squibb and Pierre Fabre Provide Update On Vinflunine Development Status
2. Carrington Subsidiary DelSite Starts Making Test Batches of First Bird Flu Vaccine Offering Needle-free Self-Administration
3. Evotec Starts Phase II in Smoking Cessation with EVT 302
4. Synosia Starts Phase II Efficacy Trial For Rufinamide
5. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN(R)/Cyclophosphamide Trial
6. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
7. Anesiva Launches Needle-Free Zingo(TM) to Reduce Pain from IV Starts and Blood Draws in Children
8. AMT Starts Collaboration With St. Jude Childrens Research Hospital on Gene Therapy for Hemophilia B. Company Accesses Exclusive Commercial Rights to Final Therapy
9. Roche starts acquisition process of ARIUS to gain access to new screening platform for antibody therapeutics
10. Gerresheimer Starts Process to Sell off its Business Segment of Technical Plastics
11. Oncolytics Biotech Inc. Starts Patient Enrolment in U.S. Phase 2 Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)..., SEATTLE, Nov. 24 Blue Marble En...e Odessa Public Development Authority (OPDA) were ...Community Economic Revitalization Board (CERB) in ...e,s first specialty biochemical biorefinery in Lin...nificantly speed the development of our biorefiner...
(Date:11/24/2009)..., TSX VENTURE: HTL , TORONTO, Nov. 24 /PRNe...TL), formerly Calotto Capital Inc., a leading prov... the stem cell research and fertility clinic marke...ts for the third quarter ended September 30, 2009....1.46 million compared with $1.43 million in Q3 200...
(Date:11/24/2009)..., REDWOOD CITY, Calif., Nov. 24 /PRNewswire-Fir...oday announced that Randy Scott, Genomic Health,s ...l Piper Jaffray Health Care Conference in New York...T. ,, To access the live and subsequently arch...or Relations section of Genomic Health,s website a...
(Date:11/24/2009)... Chemical Abstracts Service (CAS),...s that China,s patent office is now the world,s le... chemistry. China trailed Japan,s patent office, t..., and the United States Patent and Trademark Offic...SPTO in 2005, WIPO in 2006, and exceeded Japan for...
Breaking Biology Technology:Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7Hamilton Thorne announces third quarter results 8Hamilton Thorne announces third quarter results 9Hamilton Thorne announces third quarter results 10Genomic Health to Present at Piper Jaffray Health Care Conference 2China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 2China Leads All Nations in Publication of Chemical Patents According to CAS, the World's Most Authoritative Publisher of Chemical Information 3
...ed governance structure, the benefits of nanotechn...e public will not trust the cutting-edge technolog...Emerging Nanotechnologies (PEN). Rejeski testifies...ttee on technology and innovation. , Public trus...tes Rejeski in his testimony. If government and in...
...aceuticals,Inc. (Nasdaq: ANDS ) announced today t...sults on Wednesday, April 30, 2008, after the U.S....ference call and webcast to discuss its first,quar...rovide an update on,its development programs on We...ght Time. A live webcast of the call will be avail...
...mo,BioSciences, Inc. (Nasdaq: SGMO ) today announ...r 2008 financial results on Wednesday, April 30,20...l be followed by a,conference call at 2:00 p.m. PT...nd webcast. During the conference call, the compan...her business matters., The conference call dial-i...
Other Biology Technology:Improved governance needed to realize nanotech's benefits 2Anadys Pharmaceuticals to Report First Quarter 2008 Financial Results 2Sangamo BioSciences Announces First Quarter Conference Call and Webcast 2Sangamo BioSciences Announces First Quarter Conference Call and Webcast 3
(Date:11/26/2009)...vember 2009 What are the bare essentials of life,... a cell that can survive on its own? Can we descri... how an entire organism functions as a system? The...in a partnership between the European Molecular Bi...d the Centre de Regulacio Genmica (CRG) in Barcelo...
(Date:11/25/2009)...fighters, police officers and ambulance workers fa...Center complex. They battled to save people from t... tackled fires and evacuated as many people as the...,000 people. And making their jobs even harder was...rkers and their relatives jammed mobile networks w...
(Date:11/25/2009)...u eat may be just as vital to your health as what ...or Biological Studies. Their experiments in mice r...nds of genes in the liverthe body,s metabolic clea...ot by the body,s circadian clock as conventional w... activity of a large number of genes completely in...
Breaking Biology News(10 mins):First-ever blueprint of a minimal cell is more complex than expected 2First-ever blueprint of a minimal cell is more complex than expected 3Magic box for mission impossible 2Magic box for mission impossible 3Feeding the clock 2Feeding the clock 3Memorial Sloan Kettering Selects Artemis as Affiliate for India 14308 1Memorial Sloan Kettering Selects Artemis as Affiliate for India 14308 2Memorial Sloan Kettering Selects Artemis as Affiliate for India 14308 3MapleWorks 26apos 3B Video Application Development Technology Allows for High Level of Collaboration Cooperation 58626 1MapleWorks 26apos 3B Video Application Development Technology Allows for High Level of Collaboration Cooperation 58626 2MapleWorks 26apos 3B Video Application Development Technology Allows for High Level of Collaboration Cooperation 58626 3ZyDoc Solves Medical Data Transfer Issues with ZyDoc Messenger and Managed File Transfer 28MFT 29 Workflow Software 58622 1ZyDoc Solves Medical Data Transfer Issues with ZyDoc Messenger and Managed File Transfer 28MFT 29 Workflow Software 58622 2ZyDoc Solves Medical Data Transfer Issues with ZyDoc Messenger and Managed File Transfer 28MFT 29 Workflow Software 58622 3ZyDoc Solves Medical Data Transfer Issues with ZyDoc Messenger and Managed File Transfer 28MFT 29 Workflow Software 58622 4
...REDWOOD SHORES, Calif., Sept. 10 ,Communication In...("CIC"),a leading supplier of electronic signature...financial industry and the recognized leader in bi...e appointment of Michael Betts to,the CIC Board of...ence in the insurance and,financial services indus...
..., Blacksburg, Va. An international team of scien...etter and uses water more efficiently than other r...Bioinformatics Institute (VBI) has been working wi...Mexico and The Netherlands to identify, characteri...oves key features of this important grain crop. Th...
..., Two Louisiana Tech faculty members, Dr. Sumeet ...nd Dr. Rastko Selmic, an assistant professor of el...echnical knowledge to help the U.S. Air Force and ...cking capabilities. , Duas project, called Automa...s the development of fast and accurate computer al...
Other Biology News:Michael A. Betts, Seasoned Financial Services Executive, Joins CIC Board of Directors 2Michael A. Betts, Seasoned Financial Services Executive, Joins CIC Board of Directors 3HARDY rice: less water, more food 2HARDY rice: less water, more food 3Louisiana Tech researchers investigate tracking, sensors to assist Air Force 2Louisiana Tech researchers investigate tracking, sensors to assist Air Force 3
Mouse Anti-CBF-B Monoclonal Antibody, Unconjugated, Clone G-2 from Santa Cruz Biotechnology, Inc.
Mouse Anti-HSV-2 gD Monoclonal Antibody, Unconjugated, Clone 0191 from Santa Cruz Biotechnology, Inc.
...ntains 5 ml Dynabeads Epoxy (4.5 m). Hydrophobic ...roups. Ideal for coupling of antibodies for cell a... on initial coupling with covalent binding of prim...)) occurring within 16-20 hours. Coupling reaction...
Mouse Anti-St. Louis encephalitis Monoclonal Antibody, Unconjugated, Clone 6B5A-2 from ABR-Affinity BioReagents
Biology Products: